Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy. The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of life using the Kansas City Cardiomyopathy Questionnaire Overall Summary, and composite endpoints of mortality and hospitalization.
myBinderRelated Content
-
Clinical Trials: Benefits, Risks, and SafetyYou may ask yourself, "Why should I tr...
-
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR AmyloidosisThe FDA today granted Alnylam Pharmaceut...
-
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: a plain language summaryWhat is this plain language summary abou...
-
FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated AmyloidosisThe FDA announced that it has approved p...
-
Future AL Amyloidosis Treatmenthttps://www.youtube.com/watch?v=K25lurau...
-
Dr. Rosenzweig Discusses the Standard of Care in Amyloidosishttps://www.youtube.com/watch?v=5lewKqzm...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
